Pulse Biosciences Quarterly Income Statement
NASDAQ: PLSEHealthcareMedical Instruments & SuppliesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pulse Biosciences revenue and earnings
In the quarter ended Jun 30, 2026, Pulse Biosciences generated $434,000 in revenue, up 0.0% from the same quarter a year earlier. Pulse Biosciences reported a net loss of $24.7 million, compared with a loss of $19.2 million a year earlier. Gross margin was 37.1% and operating margin -5823.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Pulse Biosciences income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 434.00K | 401.00K | 264.00K | 86.00K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Cost of Revenue | 273.00K | 370.00K | 260.00K | 279.00K | 0 | 0 | 0 | 0 | — | — | 0 | 0 |
| Gross Profit | 161.00K | 31.00K | 4.00K | -193.00K | 0 | 0 | 0 | 0 | — | — | 0 | 0 |
| Operating Expenses | 25.43M | 19.18M | 18.26M | 20.17M | 20.27M | 18.04M | 20.26M | 13.65M | — | — | 12.53M | 11.25M |
| Research & Development | 16.98M | 12.59M | 10.93M | 11.39M | 12.09M | 10.31M | 10.66M | 7.70M | 7.23M | 6.74M | 7.80M | 7.47M |
| Selling, General & Admin | 8.46M | 6.59M | 7.33M | 8.78M | 8.19M | 7.73M | 9.60M | 5.95M | — | — | — | — |
| Operating Income | -25.27M | -19.15M | -18.25M | -20.37M | -20.27M | -18.04M | -20.26M | -13.65M | -11.73M | -10.62M | -12.53M | -11.25M |
| Other Income (Expense) | 615.00K | 569.00K | 820.00K | 982.00K | 1.11M | 1.25M | 876.00K | 975.00K | 343.00K | 478.00K | 600.00K | 686.00K |
| Pretax Income | — | — | — | — | -19.17M | -16.80M | 87.80M | -12.68M | -11.38M | -10.14M | -11.93M | -10.57M |
| Income Tax | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -24.66M | -18.58M | -17.43M | -19.39M | -19.17M | -16.80M | -19.39M | -12.68M | -11.38M | -10.14M | -11.93M | -10.57M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.36 | -0.27 | -0.26 | -0.29 | -0.28 | -0.25 | -0.33 | -0.21 | -0.20 | -0.18 | -0.18 | -0.19 |
| Shares Outstanding (Basic) | 69.20M | 67.99M | — | 67.39M | 67.28M | 67.13M | — | 61.07M | 57.18M | 57.12M | — | 56.87M |
| EBITDA | -25.18M | -19.06M | -18.16M | -20.27M | -20.18M | -17.93M | -20.14M | -13.55M | -11.63M | -10.48M | -12.39M | -11.15M |
| Gross Margin | 37.10% | 7.73% | 1.52% | -224.42% | — | — | — | — | — | — | — | — |
| Operating Margin | -5823.04% | -4775.56% | -6914.02% | -23682.56% | — | — | — | — | — | — | — | — |
| Net Margin | -5681.34% | -4633.67% | -6603.41% | -22540.70% | — | — | — | — | — | — | — | — |
This table shows 12 quarterly periods of Pulse Biosciences's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow PLSE's reporting calendar. What is a income statement?